Sulfadoxine + pyrimethamine


Concise Prescribing Info
Indications/Uses
Acute attack of chloroquine-resistant falciparum malaria.
Dosage/Direction for Use
Adult: PO Per tab contains sulfadoxine 500 mg and pyrimethamine 25 mg: 2-3 tabs as a single dose. Do not repeat w/in 7 days.
Contraindications
Severe renal or hepatic impairment, blood dyscrasias, hypersensitivity to components, megaloblastic anaemia due to folate deficiency, pregnancy at term and during lactation, infants ≤ 2 mth old.
Special Precautions
Impaired renal or hepatic function, folate deficiency, severe allergy or bronchial asthma, G6PD deficiency, pregnancy. Take with plenty of water to prevent crystalluria. Avoid excessive exposure to sun. Discontinue at the first sign of rash. Discontinue if signs of folic acid deficiency develops. Regular CBC monitoring, LFT, analysis of urine for crystalluria when admin for > 3 mth. Take with food to minimise Gi effects (e.g. anorexia and vomiting).
Adverse Reactions
Urticaria, serum sickness, photosensitisation, arthralgia, nausea, vomiting, abdominal pain, diarrhoea, headache, peripheral neuritis, ataxia, tinnitus, vertigo, convulsions, toxic nephrosis and pulmonary infiltrates resembling eosinophilic or allergic alveolitis.
Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, blood dyscrasias, anaphylactoid reactions.
Drug Interactions
Increased halofantrine and chlorpromazine levels. Increased effects of warfarin.
CIMS Class
ATC Classification
P01BD01 - pyrimethamine ; Belongs to the class of diaminopyrimidine antimalarials.
Disclaimer: This information is independently developed by CIMS based on sulfadoxine + pyrimethamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in